Kodu・Aktsiate loetelu・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Avatud

SektorTervishoid

6.42 0.16

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

6.3

Max

6.48

Põhinäitajad
By Trading Economics
Sissetulek	36M -3.7M
Müük	16M 66M
Aktsiakasum	0.01
Kasumimarginaal	-5.67
Töötajad	416
EBITDA	54M 12M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	-11.68% downside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	1.1B 2.5B
Eelmine avamishind	6.26
Eelmine sulgemishind	6.42

Uudiste sentiment

By Acuity

100%

320 / 340 Pingereas Healthcare

Maravai LifeSciences Holdings Inc (Class A) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. aug 2026, 19:46 UTC

Maravai LifeSciences Holdings Inc shares are lower during Monday's session, trading below their 20-day moving average with no specific news to explain the decline.

31. juuli 2026, 19:36 UTC

Maravai LifeSciences Holdings Inc. shares are lower today amid broader market volatility, having previously dropped to a session low before partially recovering.

30. juuli 2026, 16:56 UTC

Maravai LifeSciences Holdings Inc shares are gaining amid broader market recovery, with the S&P 500 advancing as investors engage in bargain hunting.

29. juuli 2026, 20:09 UTC

Maravai LifeSciences Holdings Inc shares declined during Wednesday's session, pulling back from earlier gains amid broader market volatility and rising oil prices.

28. juuli 2026, 18:06 UTC

Maravai LifeSciences Holdings Inc is gaining during Tuesday's session, though it pulled back from earlier highs amid broader market pressure in the tech sector.

24. juuli 2026, 19:36 UTC

Maravai LifeSciences Holdings Inc shares are lower amid broader market pressures, reflecting declines in the Nasdaq 100 following disappointing earnings from major tech companies.

23. juuli 2026, 09:01 UTC

Maravai LifeSciences Holdings Inc. shares are lower in pre-market trading, continuing a decline since Wednesday's close without significant recovery.

22. juuli 2026, 19:56 UTC

Maravai LifeSciences Holdings Inc. shares are lower today, retracing from earlier highs amid no specific company news. The stock remains above its 20-day moving average.

21. juuli 2026, 19:56 UTC

News

Maravai LifeSciences' TriLink BioTechnologies secures a patent for CleanCap® technology in China, boosting confidence in RNA-based therapies. Shares are higher since Monday's close.

20. juuli 2026, 20:02 UTC

Maravai LifeSciences Holdings Inc shares are lower amid broader market declines. The stock hit a session low earlier but has since recovered slightly.

Võrdlus sarnastega

Hinnamuutus

Maravai LifeSciences Holdings Inc (Class A) Prognoos

Hinnasiht

By TipRanks

-11.68% langus

12 kuu keskmine prognoos

Keskmine 5.67 USD -11.68%

Kõrge 6 USD

Madal 5 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Maravai LifeSciences Holdings Inc (Class A) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Maravai LifeSciences Holdings Inc (Class A) aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

320 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.